“The cross-contamination thing is unacceptable,” he said, “period.”
About 60 million additional doses were found to be contaminated in June.
Fuad El-Hibri was born on March 2, 1958 in Hildesheim, Germany, as the son of housewife Elizabeth (Trunk) El-Hibri and engineer and entrepreneur İbrahim El-Hibri. He grew up in Lebanon and Germany and graduated from Stanford University in 1980 with a degree in economics. He earned a master’s degree in public and private management from the Yale School of Management in 1982.
He is survived by his wife, Nancy (Grunenwald) Al-Hibri; her mother; his brother Samir; sister Yasmin El-Hibri Gibellini; his daughters Faiza and Yusra Al-Hibri; his son Karim; and three grandchildren.
Mr. Al-Hibri started his career in Saudi Arabia working for Citicorp and later worked at the consulting firm Booz Allen Hamilton in Indonesia. After returning to the United States, he started a business helping national telecom companies upgrade their networks in Russia, Venezuela, and El Salvador.
In the 1990s, he advised the Saudi Arabian government on efforts to purchase millions of doses of anthrax vaccine. This experience sowed the seed of the idea that became Emergent BioSolutions.
He co-founded the company, originally called BioPort, in 1998. He and his associates, including William J. Crowe, a former admiral, soon won a bid to purchase a disused government laboratory in Lansing, Michigan, and raise it to production. Anthrax vaccines for the US military.
The company changed its name to Emergent BioSolutions in 2004. It opened to the public in 2006.